8-K: EBR Systems' WiSE CRT System Poised for US Reimbursement as CMS Proposes NTAP Approval

EBR Systems announces that the Centers for Medicare & Medicaid Services (CMS) has proposed approval of the New Technology Add-On Payment (NTAP) for its WiSE CRT System, potentially covering a significant portion of the device cost for Medicare inpatients.

Summary

• EBR Systems has announced that CMS is proposing approval for NTAP reimbursement for its WiSE CRT System.
• CMS has recommended the maximum add-on payment of 65% of the device cost, in addition to the standard MS-DRG payment.
• This NTAP approval, if finalized, will be effective from October 1, 2025, and last for three years.
• The company intends to apply for Transitional Pass-through (TPT) reimbursement for outpatients.
• The NTAP is designed to bridge the financial gap between innovative technologies' costs and the standard Medicare payment structure.
• The WiSE CRT System meets the criteria for NTAP due to its newness, cost, and substantial clinical improvement.
• The final rule from CMS is expected in August 2025.
• NTAP reimbursement will reduce financial barriers for patients and support EBR's commercialization strategy.

Sentiment

Score: 8

Explanation: The announcement is positive due to the proposed NTAP approval, which is a significant step towards commercialization and reimbursement for the WiSE CRT System; the maximum add-on payment further enhances the positive outlook.

Positives

• The proposed NTAP approval represents a significant milestone in EBR's commercialization strategy.
• The 65% add-on payment is expected to fully cover the cost of the WiSE System.
• NTAP reimbursement will improve patient access to the technology and accelerate market adoption.
• The company is also pursuing reimbursement for outpatient procedures.

Risks

• The NTAP approval is subject to the final rule by CMS, expected in August 2025.
• The company's ability to commercialize its products depends on obtaining reimbursement for those products.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

EBR Systems anticipates the NTAP will be finalized in Q3 2025, furthering its US commercialization strategy to accelerate market adoption and enable widespread access in the US; the company also intends to apply for Transitional Pass-through (TPT) reimbursement for outpatients.

Management Comments

• John McCutcheon, EBR Systems President & Chief Executive Officer, stated that the proposed NTAP approval at the maximum rate of 65% of the device cost builds on the news of FDA approval and brings the company closer to delivering its technology to patients being treated as inpatients.

Industry Context

This announcement is significant in the context of the medical device industry, where reimbursement is a critical factor for the adoption of new technologies; NTAP approval can provide a substantial boost to the commercial success of innovative devices like the WiSE CRT System.

Comparison to Industry Standards

• NTAP approval is a common pathway for innovative medical devices to gain reimbursement in the US.
• Companies like Medtronic, Boston Scientific, and Abbott have previously utilized NTAP for their novel technologies.
• The 65% add-on payment is a substantial level of reimbursement, indicating CMS's recognition of the value of the WiSE CRT System.

Stakeholder Impact

• Shareholders: Positive impact due to potential for increased revenue and market adoption.
• Patients: Improved access to innovative cardiac pacing technology.
• Customers (Hospitals): Reduced financial barriers for adopting the WiSE CRT System.

Next Steps

• CMS final rule expected in August 2025.
• EBR Systems to apply for Transitional Pass-through (TPT) reimbursement for outpatients.
• Commercialization efforts to accelerate market adoption in the US.

Key Dates

Keywords

WiSE CRT System, NTAP, CMS, reimbursement, cardiac pacing, EBR Systems, heart failure, medical device